Authors' reply to McKenna-Barry and Ryan
- PMID: 31757800
- DOI: 10.1136/bmj.l6549
Authors' reply to McKenna-Barry and Ryan
Conflict of interest statement
Competing interests: NS reports personal fees from AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Janssen, and Sanofi and a grant from Boehringer Ingelheim. WA reports consultancy and sponsored lectures from Gilead, GlaxoSmithKline, Intercept IQVIA, and UCB Pharma.
Comment on
-
Studies on non-alcoholic fatty liver disease should stratify by disease severity.BMJ. 2019 Nov 22;367:l6495. doi: 10.1136/bmj.l6495. BMJ. 2019. PMID: 31757812 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical